On August 12, 2019 Chemesis International (CSI.C) announced that it will start manufacturing, packaging and distributing its own line of tobacco-free smokeless cannabis and hemp-derived chew in Puerto Rico and Canada and the U.S.
Ichiro Suzuki – a recently retired major league baseball player – hit only 117 home runs in 9,934 career at bats. That’s a 1.2% home run success ratio. Yet Suzuki is considered one of the most effective batters ever to play the game.
Reading Chemesis International’s (CSI.C)‘s July 26, 2019 “operational and corporate update” is like watching footage of a toddler vacuuming a living room.
In the cannabis “Get-Big-Fast” era, where weed companies buy stuff (grow-ops, dispensaries, websites, manufacturing plants, brands etc.) and post gigantic quarterly losses, it’s refreshing to see one company do it the old-fashioned way.
Equity.Guru podcast: Chemesis International (CSI.C) angles for piece of $627 million LatAm cannabis market
On April 15, 2019 Chemesis International (CSI.C) announced plans to purchase a cannabis manufacturing facility in Arizona, that is already up-and-running, generating about $1.3 million in Q1, 2019.
On April 9, 2019 Chemesis International (CSI.C) announced that it will “produce and distribute its all-natural CBD product line Viverian, in Puerto Rico, through its subsidiary Natural Ventures.”